Kornimate/medical-research-clean huggingface dataset:
cardiac rehabilitation with and without delorme technique of progressive resisted exercises in patients of post pci.

Conditions: Percutaneous CORONARY INTERVENTION

Summary: to find the effect of cardiac rehabilitation program with and without progressive resisted exercises on patients after acute stage of pci with at least 8 weeks history. it is a randomized clinical trial using convenient sampling technique. randomly assign participants into two groups: an intervention group receiving delorme progressive resisted exercise along with cardiac rehab and a control group undergoing standard cardiac rehabilitation alone. in group a, delorme technique will involve a 10-repetition max of aerobic and resistance exercises along with cardiac rehab. seven different exercises will be performed in 3 sets of 10-repetition max. the control group will not be performing any type of training but will undergo cardiac rehab alone. data will be analyzed using t test and spss 21 will be used for data collection. age group will be from ≥70 years with patient undergoing dyspnea along with recent history of primary diseases. data will be collected from bethania hospital, sialkot through tools like the 6-minute walk test, rose angina questionnaire or settle angina questionnaire, quality of life scale (qolfs), and modified borg dyspnea scale.


Eligibility criteria:
inclusion criteria: * age: ≥ 70 years" * "recent history of pci due to primary diseases (coronary heart disease, acute myocardial infarction, acute coronary syndrome, acute angina)" * "presence of dyspnea" * "first-time pci exclusion criteria: * "renal failure" * chronic liver disease * chest disease * patient who could not fulfill the questionnaire or cooperate through the performed procedures

Keywords: quality of life cardiac rehabilitation delorme technique
iv sildenafil persistent pulmonary hypertension of the newborn

Conditions: Persistent Pulmonary Hypertension of the Newborn

Summary: to determine the efficacy of iv sildenafil in term and near term infants with pphn (persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric oxide (ino) or extracorporeal membrane oxygenation (ecmo) compared to a historical control group not treated with sildenafil.


Eligibility criteria:
inclusion criteria: * babies \< 72 hours old and at least 34 gestational weeks with pphn or hypoxic respiratory failure associated with idiopathic pphn, meconium aspiration, sepsis or pneumonia * oxygenation index \>15 and \< 60 exclusion criteria: * congenital anomaly * large left to right intracardiac or ductal shunt * already on inhaled nitric oxide

Keywords: pphn persistent pulmonary hypertension of the newborn sildenafil iv
mechanisms of sleep latency and health: the effect of a melatonin receptor agonist in inflammation and insulin resistance

Conditions: Insomnia

Summary: the purpose of this study is to help scientist better understand the effect of a 12-week single daily evening dose of ramelteon (rozerem ©), a drug that has been approved by the u. s. food and drug administration (fda) for the treatment of insomnia (trouble falling asleep or staying asleep). the study will measure levels of inflammation, fasting insulin and fasting glucose (sugar) in subjects who are taking either ramelteon (8 mg) or placebo.


Eligibility criteria:
inclusion criteria: at screening visit: * aged 18-65 * nonsmokers * for women: oral contraceptive (oc) or hormone replacement therapy (hrt) nonusers to schedule the baseline psg (visit 2), subjects must meet the following inclusion criteria: * ages 18-65 inclusive; * psqi-component 2 (sleep latency) score of greater than 1; * non-smoker (e.g., less than 20 cigarettes in the past 5 years); * habitual bedtime between 8:30 pm and midnight * for premenopausal women: * regular menstrual cycles determined by framingham study criteria; * not pregnant and no history of oral contraceptive (oc) usage in last 6-months. * for postmenopausal women: * no recent (\< 6 months) use of hormone replacement therapy (hrt) * no surgical menopause exclusion criteria: * positive urine drug screen * potential subjects with hypersensitivity to ramelteon or any components of the formulation will be excluded from participation. * given that ramelteon should not be used by individuals with severe hepatic impairment, or in patients in combination with fluvoxamine, individuals who report liver problem or use of fluvox will be excluded. * use of rifampin (rifadin ©); ketoconazole (nizora ©l); or fluconazole (diflucan ©). * ramelteon has not been studied in children or adolescents, and the effects in these populations are unknown, thus only individuals above 18 years will participate.

Keywords: insomnia
open label extension study of bifeprunox

Conditions: Schizophrenia

Summary: a one year extension study using flexible doses, 20 or 30 mg daily, of open-label bifeprunox.


Eligibility criteria:
inclusion criteria: 1. outpatients who have successfully completed wyeth study 3168a1-311-us. 2. a signed and dated informed consent form for this study. 3. no major protocol violations in previous study. exclusion criteria: 1. clinically important abnormalities noted in preceding short-term study that have not resolved. 2. use of prohibited treatments in the preceding short-term study. 3. meeting any exclusion criteria for the preceding short-term study.

Keywords: schizophrenia
the role and mechanism of gper-hippo-cbs/h2s pathway in preeclampsia

Conditions: Preeclampsia

Summary: the goal of this clinical trial is to learn about in health conditions. the main questions it aims to answer are: * the pathological significance of gper in uterine artery dilation in preeclampsia * the mechanism of gper hippo pathway regulating cbs/h2s in human uterine artery smooth muscle cells (huasmc) this project intends to use gper interfering rna, yap1 interfering rna, in vivo perfusion experiments of human uterine artery tissue, and single cell patch clamp technology to study hypotheses under physiological/pathological pregnancy conditions at the tissue, cellular, and molecular levels, revealing a novel signal transduction pathway of estrogen stimulating vasodilation, providing new ideas for studying the mechanism of uterine artery blood flow regulation. this research result will provide new targets for intervention and treatment of diseases such as fetal intrauterine growth retardation and preeclampsia.

1. measure the content of h2s in uterine arterial smooth muscle and circulation of normal pregnancy and pe pregnant women, and analyze the relationship between the content of h2s in uterine arterial smooth muscle and circulation of pe pregnant women and pe. 2. knock down the gper and overexpression of gper in htr-8 cells, and detect the expression of gper, cbs, and hippo pathway related proteins using western blot and qrt-pcr to verify the efficiency of knockdown and overexpression. use different concentrations of h2s donor (gyy4137) to interfere with htr-8 cells after treatment, and use rt-pcr and western blot to detect the mrna and protein expression of downstream molecules yap and taz in hippo pathway in cells, respectively.

Eligibility criteria:
inclusion criteria: 1. full term pregnancy with clinical diagnosis of preeclampsia and normal pregnancy pregnant woman 2. pregnant women undergoing lower segment cesarean section for delivery exclusion criteria: 1. combined with chronic hypertension, kidney disease, intrahepatic cholestasis, etc other basic diseases; 2. multiple pregnancy 3. pregnant women undergoing vaginal delivery 4. normal pregnant women who are\ 40 weeks pregnant

Keywords: preeclampsia
open-label extension of zilucoplan in subjects with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis

Summary: the raise-xt study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gmg who have previously participated in a qualifying ra pharmaceuticals sponsored zilucoplan study.


Eligibility criteria:
inclusion criteria: * completion of a qualifying zilucoplan study exclusion criteria: * with the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)
re-licensing study to assess virosomal influenza vaccine formulated with who recommended influenza strains

Conditions: Influenza

Summary: the study is to assess whether the virosomal influenza vaccine for season 2012/2013 fulfills the ema requirements for re-registration of influenza vaccines.


Eligibility criteria:
inclusion criteria: * healthy female and male adults aged ≥18 on day 1 * written informed consent * female subjects of childbearing potential using and willing to continue using an acceptable method of contraception unless surgically sterilized/hysterectomized or post-menopausal for more than 2 years exclusion criteria: * acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * acute febrile illness (≥38.0 °c) * prior vaccination with an influenza vaccine in the past 330 days * known hypersensitivity to any vaccine component * previous history of a serious adverse reaction to influenza vaccine * history of egg protein allergy or severe atopy * known blood coagulation disorder * chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of the study vaccine, including oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled or topical steroids are allowed) * known immunodeficiency (incl. leukemia, hiv seropositivity), cancer * investigational medicinal product received in the past 3 months (90 days) starting from the first day of the month following the last visit in a previous study * treatment with immunoglobulins or blood transfusion(s) received in the past 3 months (90 days) * pregnancy or lactation * participation in another clinical trial * employee at the investigational site, or relative of the investigator * subjects who in the view of the investigator will not comply with study procedures and/or visit requirements as per protocol

Keywords: influenza virus vaccination virosomal influenza vaccine
dexamethasone and covid-19 inpatient mortality

Conditions: Coronavirus

Summary: the study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among us patients hospitalized with covid-19 diagnosis or sars-cov-2 infection, overall and stratified by covid-19 severity subgroups.

this is a non-randomized, non-interventional study that is part of a research collaboration agreement between the us food and drug administration (fda) and aetion to use real-world data to advance the understanding and the natural history of covid-19 in specific patient populations, as well as treatment and diagnostic patterns during the coronavirus disease (covid-19) pandemic. this study compares inpatient mortality within 28 days among us patients hospitalized with covid-19 diagnosis or sars-cov-2 infection who initiate dexamethasone treatment with a matched cohort of patients with 'standard of care' who are non-users of corticosteroids of interest (dexamethasone, prednisone, methylprednisolone, hydrocortisone). patients are compared overall and and stratified by covid-19 severity subgroups.

Eligibility criteria:
inclusion criteria: * hospitalized patients with confirmed covid-19 (diagnosis of u07.1 or positive or presumptive positive sars-cov-2 diagnostic laboratory test result) occurring between 21 days prior to the hospital admission date and the treatment index date. exclusion criteria: * no interaction with the healthcare system (medical encounter) in the 183 days prior to and including hospital admission (day -183 to day 0) to minimize the potential for misclassification of baseline covariates and/or new use * no age or sex recorded in the 183 days prior to and including hospital admission (day -183 to day 0) as required for matching * no geographic region recorded in 183 days prior to and including hospital admission (day -183 to day 0) as necessary to adjust for regional variation * any recorded use of any csi (dispensing or remaining supply) in the 90-day washout prior to the treatment index date (day t-90 to day t-1) to satisfy new use definition * any record of a covid-19 vaccine recorded on or any time prior to the treatment index date given that these patients are assumed to be selectively different (day s to day t)

Keywords: treatment dexamethasone corticosteroid mortality
acute side effects in patients who are undergoing stereotactic radiosurgery for brain tumors or other brain disorders

Conditions: Brain and Central Nervous System Tumors; Metastatic Cancer; Radiation Toxicity

Summary: rationale: learning about the side effects of stereotactic radiosurgery in patients with brain tumors or other brain disorders may help doctors plan treatment and help patients live more comfortably. purpose: this clinical trial is studying the acute side effects in patients who are undergoing stereotactic radiosurgery for brain tumors or other brain disorders.

objectives: * determine the incidence and types of acute complications in patients undergoing stereotactic radiosurgery for brain tumors or other brain disorders. * determine the time frame for development and resolution of these complications in these patients. * determine the severity of these complications in these patients. outline: patients undergo stereotactic radiosurgery. patients also complete questionnaires about the side effects they experience from radiosurgery. the questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery. projected accrual: a total of 94 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of brain tumor or other brain disorder, including, but not limited to, 1 of the following: * primary brain tumors * brain metastases * acoustic neuromas * pituitary adenomas * parkinson's disease * cluster headaches * glomus jugulare * epilepsy * obsessive compulsive disorder * arteriovenous malformations * trigeminal neuralgia * eligible for and scheduled to undergo stereotactic radiosurgery patient characteristics: performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * no physical or mental limitation that would preclude study compliance prior concurrent therapy: endocrine therapy * concurrent steroids allowed radiotherapy * no prior stereotactic radiosurgery

Keywords: radiation toxicity tumors metastatic to brain adult anaplastic astrocytoma adult anaplastic ependymoma adult anaplastic meningioma adult anaplastic oligodendroglioma adult brain stem glioma adult central nervous system germ cell tumor adult choroid plexus tumor adult craniopharyngioma adult diffuse astrocytoma adult ependymoblastoma adult ependymoma adult giant cell glioblastoma adult gliosarcoma adult medulloblastoma adult melanocytic lesion adult meningeal hemangiopericytoma adult meningioma adult myxopapillary ependymoma adult oligodendroglioma adult papillary meningioma adult pineoblastoma adult pineocytoma adult subependymoma adult supratentorial primitive neuroectodermal tumor (pnet) adult grade i meningioma adult grade ii meningioma adult grade iii meningioma adult mixed glioma recurrent adult brain tumor adult pilocytic astrocytoma adult glioblastoma acth-producing pituitary tumor growth hormone-producing pituitary tumor nonfunctioning pituitary tumor prolactin-producing pituitary tumor recurrent pituitary tumor tsh producing pituitary tumor
non-invasive mrd assessment in multiple myeloma

Conditions: Myeloma

Summary: the purpose of this study is to investigate the sensitivity and accuracy of non-invasive mrd assessment using liquid biopsy (blood draw) and functional imaging (whole body mri) in participants with new diagnosed and previously treated multiple myeloma. the long-term goal of this study is to investigate whether non-invasive methods for mrd assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.

there is an unmet clinical need for an easier, non-invasive, and reliable method to perform mrd assessments that can be used in clinical trials and routine practice. the two non-invasive modalities that are most promising for mrd assessment are liquid biopsy to detect circulating tumor cells (ctcs) and functional imaging to detect focal myeloma lesions. however, there are no prospective data on the sensitivity and specificity of non-invasive mrd assessment with respect to the gold standard of bone marrow sampling.

Eligibility criteria:
inclusion criteria: * adults age ≥18 years * patients with newly diagnosed multiple myeloma * patients with previously treated multiple myeloma with a maximum of two prior lines of therapy * expected life expectancy of greater than one year and intention to start a new line of treatment exclusion criteria: * patients without cognitive capacity to give informed consent for participation * patients with contraindications to mri, which include the following: * claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (wb-dwi) * pacemaker * metallic implants, which would prohibit patient from undergoing mri all subjects will be screened for any contraindication to mri as per their guidelines at the time of patient enrollment. * patients must not receive granulocyte colony stimulating factor (g-csf) or granulocyte-macrophage colony-stimulating factor (gm-csf) injection within 1 week prior to wb-dwi. * patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/biopsy and/or wb-dwi up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- cyclophosphamide-dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and wb-dwi.

Keywords: liquid biopsy minimal residual disease (mrd) functional imaging
the effect of mandala coloring on depression, anxiety and quality of life of inpatients in a psychiatric clinic

Conditions: Depression; Anxiety

Summary: the aim of this study is to examine the effects of mandala coloring activity applied to individuals hospitalized in a psychiatric clinic with a diagnosis of anxiety and depression disorder on quality of life, psychological resilience and depression, anxiety and stress levels.

introduction: it is stated that healthcare professional-patient interaction and patient activity improve clinical outcomes for patients with mental illness. when compared to psychosocial interventions, the most commonly used method in 49% of clinics was found to be artistic practices. it is stated that mandala painting has a calming and healing effect on the individual, facilitating psychological integration and personal meaning in life. objective: the aim of this study is to examine the effects of mandala coloring activity applied to individuals hospitalized in a psychiatric clinic with a diagnosis of anxiety and depression disorder on quality of life, psychological resilience and depression, anxiety and stress levels. method: the research will be conducted using a randomized controlled experimental research design. the research sample will consist of 50 patients in a university hospital psychiatry clinic. research data will be collected using the introductory information form, depression-anxiety-stress scale short form, quality of life scale (sf-12), and brief resilience scale. patients diagnosed with anxiety and depression will undergo 8 sessions of mandala application. data will be collected in two time periods before starting the mandala application and at the end of the 8-session application.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the study * being 18 years of age or older * diagnosed with anxiety and depression disorder exclusion criteria: * those who gave incomplete answers to the scales used in the study * those with serious psychiatric symptoms (e.g. harming themselves or others, sedation) * those who did not participate in the mandala coloring session * those who did not agree to participate in the study
oral versus vaginal progesterone for luteal phase supplementation in frozen embryo transfer cycles

Conditions: Frozen Embryo Transfer; Hormone Replacement Therapy; Dydrogesterone; Infertility, Female

Summary: to investigate the efficacy of dydrogesterone 30 mg compared to micronized vaginal progesterone 800 mg daily for luteal phase support in hormone replacement therapy frozen embryo transfer cycles, as confirmed by visualization of fetal heart activity by pelvic ultrasound assessment of ongoing pregnancy at 12 weeks of gestation.

a randomized controlled trial comparing dydrogesterone 30 mg versus micronized vaginal progesterone 800 mg daily for luteal phase support in hormone replacement therapy frozen embryo transfer cycles. patients will undergo an embryo transfer in a hormone replacement therapy cycle using progynova 2 mg three times daily until an endometrium thickness of at least 7 mm is reached. afterwards two different luteal phase supplementation methods will be compared. the primary outcome of the study is ongoing pregnancy at 12 weeks of gestation. we will also investigate other prenatal and neonatal outcome factors as well as patients satisfaction and safety of dydrogesterone.

Eligibility criteria:
inclusion criteria: * ≤40 years of age at the time of ivf/icsi treatment * bmi ≥18 to ≤30 kg/m2 with a documented history of infertility * have undergone cos as part of an art treatment and have had an unsuccessful fresh embryo transfer in that cycle, or, have undergone freeze all strategy * scheduled to undergo fet with a standard exogenous/programmed hormonal replacement therapy (hrt) regimen * have at least 1 blastocyst vitrified on the 5th or 6th day after oocyte retrieval * elective single embryo (blastocyst) transfer (set) * normal ultrasound examination at enrollment (or if \<12 months old) * signed patient authorization for use/disclosure of data. exclusion criteria: * women with a history of recurrent miscarriage, defined as \>2 consecutive miscarriages (biochemical pregnancy losses are not included) * absence of implantation (serum hcg = negative) after two consecutive cycles of ivf, icsi or fet where the cumulative number of transferred embryos was \>4 cleavage-stage embryos and \>2 blastocysts * presence of hydrosalpinx that is not surgically treated * endometrial abnormalities on scanning during ovarian stimulation, such as endometrial polyp(s), sub mucosal fibroid(s), endometrial hyperplasia, endometrial fluid accumulation, or endometrial adhesions * participating in another clinical study at the same time * known allergic reactions to dydrogesterone or other progestogens products * any contraindication or other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions listed in the locally approved label * mental disability or any other lack of fitness, in the investigator's opinion, to preclude subjects in or to complete the study * history of prior chemotherapy * contraindication for pregnancy * transfer of \>1 embryo